To study the efficacy of nimodipine in the treatment of acute ischemic stroke.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized, double-blind, placebo-controlled trial of 164 patients.
Patients were randomized to receive intravenous nimodipine (day 1-10: 2mg/hr, day 11-6 months:180mg/day orally) or placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Toronto Stroke Scale, functional disability, and deaths during 1 year follow-up period.|